Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) kicked off on Monday, up 3.12% from the previous trading day, before settling in for the closing price of $42.37. Over the past 52 weeks, RARE has traded in a range of $31.52-$54.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 63.06%. While this was happening, its average annual earnings per share was recorded 21.76%. With a float of $77.02 million, this company’s outstanding shares have now reached $82.31 million.
The extent of productivity of a business whose workforce counts for 1276 workers is very important to gauge.
Ultragenyx Pharmaceutical Inc. (RARE) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ultragenyx Pharmaceutical Inc. is 6.45%, while institutional ownership is 104.17%. The most recent insider transaction that took place on Apr 18 ’24, was worth 6,262. In this transaction EVP and Chief Medical Officer of this company sold 142 shares at a rate of $44.10, taking the stock ownership to the 48,785 shares. Before that another transaction happened on Mar 11 ’24, when Company’s CBO & EVP sold 11,509 for $49.93, making the entire transaction worth $574,644. This insider now owns 252,823 shares in total.
Ultragenyx Pharmaceutical Inc. (RARE) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 21.76% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.90% during the next five years compared to -15.75% drop over the previous five years of trading.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Trading Performance Indicators
Take a look at Ultragenyx Pharmaceutical Inc.’s (RARE) current performance indicators. Last quarter, stock had a quick ratio of 2.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.33, a number that is poised to hit -1.75 in the next quarter and is forecasted to reach -5.00 in one year’s time.
Technical Analysis of Ultragenyx Pharmaceutical Inc. (RARE)
The latest stats from [Ultragenyx Pharmaceutical Inc., RARE] show that its last 5-days average volume of 0.77 million was superior to 0.76 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 15.70%. Additionally, its Average True Range was 2.23.
During the past 100 days, Ultragenyx Pharmaceutical Inc.’s (RARE) raw stochastic average was set at 37.35%, which indicates a significant increase from 22.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.86% in the past 14 days, which was higher than the 45.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $47.90, while its 200-day Moving Average is $42.12. Now, the first resistance to watch is $44.62. This is followed by the second major resistance level at $45.55. The third major resistance level sits at $46.66. If the price goes on to break the first support level at $42.58, it is likely to go to the next support level at $41.47. The third support level lies at $40.54 if the price breaches the second support level.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Key Stats
The company with the Market Capitalisation of 3.60 billion has total of 82,300K Shares Outstanding. Its annual sales at the moment are 434,250 K in contrast with the sum of -606,640 K annual income. Company’s last quarter sales were recorded 127,390 K and last quarter income was -123,190 K.
